The Future of Skin Cancer Treatment May Be Personalized

You are unique. There is no one in the world exactly like you.

This individuality is the driving force behind a revolutionary new vaccine for skin cancer patients.

Making its way through clinical trials, the TLPLDC (tumor lysate, particle-loaded, dendritic cell) vaccine by Elios Therapeutics is personalized for each patient. It is created from the patient’s own blood and tumor cells. This makes for medication as unique as the person taking it.

TLPLDC (tumor lysate, particle-loaded, dendritic cell) vaccine

Photo Courtesy of Elios Therapeutics

The vaccine is intended for patients with Stage III or IV melanoma at high risk of recurrence following surgical resection. Initial study data is promising with a 93% increase in 3-year survival rates without the disease returning.

“These new data, combined with the doubled rate of disease-free survival among patients treated with the vaccine and standard of care checkpoint inhibitors, further strengthen our confidence that the personalized TLPLDC vaccine provides a clinically meaningful benefit for people with high-risk melanoma,” said Buddy Long, CEO of Elios Therapeutics in a recent press release.

This personalized approach seems a great way to treat the person rather than just the disease. Could the future of other therapies be custom tailored for each individual patient?